

DRONE DELIVERY CANADA CORP.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED

SEPTEMBER 30, 2021 AND 2020

(UNAUDITED)

MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING

The accompanying unaudited condensed consolidated interim financial statements of Drone Delivery Canada Corp. (the "Company") are the responsibility of management and the Board of Directors.

The unaudited condensed interim consolidated financial statements have been prepared by management, on behalf of the Board of Directors, in accordance with the accounting policies disclosed in the notes to the unaudited condensed interim consolidated financial statements. Where necessary, management has made informed judgments and estimates in accounting for transactions which were not complete at the statement of financial position date. In the opinion of management, the unaudited condensed interim consolidated financial statements have been prepared within acceptable limits of materiality and are in accordance with International Accounting Standard 34 - Interim Financial Reporting using accounting policies consistent with International Financial Reporting Standards appropriate in the circumstances.

Management has established processes, which are in place to provide it with sufficient knowledge to support management representations that it has exercised reasonable diligence in that (i) the unaudited condensed interim financial statements do not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it is made, as of the date of, and for the periods presented by, the unaudited condensed interim consolidated financial statements and (ii) the unaudited condensed consolidated interim financial statements fairly present in all material respects the financial condition, results of operations and cash flows of the Company, as of the date of and for the periods presented by the unaudited condensed interim consolidated financial statements.

The Board of Directors is responsible for reviewing and approving the unaudited condensed interim consolidated financial statements together with other financial information of the Company and for ensuring that management fulfills its financial reporting responsibilities. An Audit Committee assists the Board of Directors in fulfilling this responsibility. The Audit Committee meets with management to review the financial reporting process and the unaudited condensed interim consolidated financial statements together with other financial information of the Company. The Audit Committee reports its findings to the Board of Directors for its consideration in approving the unaudited condensed interim consolidated financial statements together with other financial information of the Company for issuance to the shareholders.

Management recognizes its responsibility for conducting the Company's affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

NOTICE TO READER

The accompanying condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of management. The financial statements have not been reviewed by the Company's auditors.

Condensed Interim Consolidated Statements of Financial Position

(Expressed in Canadian dollars) (Unaudited)

	Sep	otember 30, 2021	C	December 31, 2020
ASSETS				
Current				
Cash and cash equivalents	\$	31,071,646	\$	23,464,255
Trade and other receivables (Note 3)	•	116,981	,	522,848
Prepaid expenses (Note 16)		465,816		892,763
. , , ,		31,654,443		24,879,866
Equipment (Note 5)		2,349,175		2,203,564
Patents (Note 4)		800,751		750,085
Trademarks (Note 6)		104,489		94,372
Leasehold improvements (Note 7)		769,031		999,178
Right-of-use assets (Note 8)		401,558		442,274
TOTAL ASSETS	\$	36,079,447	\$	29,369,339
LIABILITIES				
Current				
Trade and other payables (Note 9, 16)	\$	1,934,757	\$	1,787,650
Lease obligations - current portion (Note 10)	·	190,836	,	175,625
-		2,125,593		1,963,275
Lease obligations - long term portion (Note 10)		259,436		308,512
TOTAL LIABILITIES		2,385,029		2,271,787
EQUITY				
Share capital		96,311,976		69,543,950
Share-based payments reserve		10,380,182		18,922,208
Deficit		(72,997,740)		(61,368,606)
TOTAL EQUITY		33,694,418		27,097,552
TOTAL LIABILITIES AND EQUITY	\$	36,079,447	\$	29,369,339

Nature of Operations (Note 1)

Approved on Behalf of the Board:

<u>Signed "Larry Taylor"</u>
Larry Taylor, Director
Signed "Michael Zahra"
Michael Zahra, CEO and Director

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Expressed in Canadian dollars) (Unaudited)

	Three Months Ended	September 30	Nine Months Ended	September 30
	2021	2020	2021	2020
REVENUE	\$ 6,286 \$	36,068 \$	219,674 \$	62,613
OPERATING EXPENSES				
Service costs and materials	82,074	1,177	254,780	42,821
Advertising and promotion	122,375	20,831	1,649,078	869,508
Depreciation and amortization	208,976	200,359	622,247	616,976
Interest expense on lease obligations	10,652	13,585	33,055	42,931
Consulting (Note 16)	458,321	785,170	1,448,629	1,478,245
Loss on disposal of equipment	28,079	-	71,926	-
Interest and bank charges	2,469	3,647	10,110	8,557
Personnel expenses (Note 16)	1,196,586	677,996	3,574,575	2,342,538
Office and general	474,685	459,840	1,190,752	1,036,140
Professional fees (Note 16)	146,955	119,198	377,644	284,788
Shareholder information	33,220	65,446	181,981	209,283
Research and development	325,658	563,969	1,259,529	1,871,193
Share based compensation	268,851	958,638	1,215,195	2,137,036
TOTAL OPERATING EXPENSES	\$ 3,358,901 \$	3,869,856 \$	11,889,501 \$	10,940,016
OPERATING LOSS	\$ (3,352,615) \$	(3,833,788) \$	(11,669,827) \$	(10,877,403)
Interest Income	(17,228)	(68,184)	(44,049)	(106,589)
Foreign exchange (gains)/losses	(8,952)	8,062	3,356	2,537
NET LOSS AND COMPREHENSIVE LOSS	\$ (3,326,435) \$	(3,773,666) \$	(11,629,134) \$	(10,773,351)
Basic and diluted loss per share (Note 14)	\$ (0.01) \$	(0.02) \$	(0.05) \$	(0.06)
Weighted average number of shares				
	222 764 502	107 440 020	221 442 452	101 224 422
outstanding - basic and diluted	223,761,502	187,448,839	221,442,453	181,324,432

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Exercise of options - valuation

Stock based compensation

Net Loss for the period

Balance, September 30, 2021

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Expressed in Canadian dollars) (Unaudited)

			Share based		
	Number of	Common	Payments		
	Shares	Shares (\$)	Reserve (\$)	Deficit (\$)	Total (\$)
Balance, December 31, 2019	177,345,089	49,150,930	13,627,437	(47,238,411)	15,539,956
Private placement, net of costs	13,225,000	8,365,569	-	-	8,365,569
Issuance of warrants	-	(1,529,472)	1,529,472	-	-
Issuance of broker warrants	-	(243,605)	243,605	-	-
Exercise of options - cash	1,910,000	955,000	-	-	955,000
Exercise of options - valuation	-	468,453	(468,453)	-	-
Stock based compensation	-	-	2,137,036	-	2,137,036
Net loss for the period	-	-	-	(10,773,351)	(10,773,351)
Balance, September 30, 2020	192,480,089	57,166,875	17,069,097	(58,011,762)	16,224,210
Balance, December 31, 2020	210,066,589	69,543,950	18,922,208	(61,368,606)	27,097,552
Exercise of broker warrants - cash	845,261	745,424	-	-	745,424
Exercise of broker warrants - valuation	-	179,399	(179,399)	-	-
Exercise of warrants - cash	3,930,500	4,873,219	-	-	4,873,219
Exercise of warrants - valuation	-	990,722	(990,722)	-	-
Exercise of options - cash	9,356,662	11,392,162	-	-	11,392,162

224,199,012

8,587,100

96,311,976

(8,587,100)

1,215,195

10,380,182

(11,629,134)

(72,997,740)

The accompanying notes form an integral part of these condensed interim consolidated financial statements.

1,215,195

(11,629,134)

33,694,418

Condensed Interim Consolidated Statements of Cash Flows

(Expressed in Canadian dollars) (Unaudited)

		Three Months Ended September 30		Nine Months Ended	September 30	
		2021	2020	2021	2020	
CASH (USED IN) PROVIDED BY:						
OPERATING ACTIVITIES						
Net loss for the period	\$	(3,326,435) \$	(3,773,666) \$	(11,629,134) \$	(10,773,351)	
Items not affecting cash:						
Depreciation of equipment and right-of-use assets		204,953	162,562	611,612	608,526	
Interest expense on lease obligations		10,652	13,585	33,055	42,931	
Amortization of patents		4,023	3,506	10,635	8,450	
Stock based compensation		268,851	958,638	1,215,195	2,137,036	
Loss on disposal of equipment		28,079	-	71,926	-	
Net change in non-cash working capital:						
Trade and other receivables		(65,483)	28,492	405,867	2,762,421	
Prepaid expenses		298,339	(53,948)	426,945	(132,697)	
Accounts payable and accrued liabilities		539,717	692,080	147,107	250,999	
NET CASH USED IN OPERATING ACTIVITIES	\$	(2,037,304) \$	(1,968,751) \$	(8,706,792) \$	(5,095,685)	
INVESTING ACTIVITIES		(72.246)	(25,606)	(454.274)	(250.054)	
Acquisition of equipment		(73,316)	(35,696)	(454,374)	(359,954)	
Acquisition of patents and trademarks		(33,676)	(44,292)	(71,418)	(98,302)	
Acquisition of leasehold improvements	_	(6,500)	45,629	(6,500)	(54,834)	
NET CASH USED IN INVESTING ACTIVITIES	\$	(113,492) \$	(34,359) \$	(532,292) \$	(513,090)	
FINANCING ACTIVITIES						
Lease payments		(56,472)	(28,447)	(164,331)	(159,645)	
Private placements, net of costs		-	8,365,569	-	8,365,569	
Proceeds from exercise of options		331,334	-	11,392,162	955,000	
Proceeds from exercise of warrants		-	-	4,873,219	-	
Proceeds from exercise of broker warrants		-	-	745,424	-	
NET CASH PROVIDED BY FINANCING ACTIVITIES	\$	274,862 \$	8,337,122 \$	16,846,474 \$	9,160,924	
INCREASE (DECREASE) IN CASH		(1,875,934)	6,334,012	7,607,390	3,552,149	
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		32,947,580	6,991,149	23,464,255	9,773,012	
CASH AND CASH EQUIVALENTS, END OF PERIOD	\$	31,071,646 \$	13,325,161 \$	31,071,646 \$	13,325,161	

SUPPLEMENTARY CASH FLOW INFORMATION:

During the three and nine months ended September 30, 2021 and 2020, non-cash activites were conducted by the Company as follows:

	Three Months Ended Se	ptember 30	Nine Months Ended September 30			
	2021	2020	2021	2020		
Investing Activities						
Acquistion of right-of-use assets	\$ (54,982) \$	- \$	(97,411) \$	-		
Financing Activities						
Increase in lease obligation	\$ 54,982 \$	- \$	97,411 \$	-		

The accompanying notes form an integral part of these condensed interim consolidated financial statements.

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

1. NATURE OF OPERATIONS

Drone Delivery Canada Corp. (the "Company") was incorporated under the Business Corporations Act (British Columbia) on February 2, 2011. The Company is a developmental technology company with a focus on designing, developing and implementing a commercially viable drone delivery system within the Canadian geography. The Company's principal office is located at 6221 Highway 7, Unit 6, Vaughan, Ontario L4H 0K8.

As at September 30, 2021, the Company had cash and cash equivalents of \$31,071,646 (December 31, 2020 - \$23,464,255) and working capital of \$29,528,850 (December 31, 2020 - \$22,916,591). Management of the Company believes that it has sufficient funds to pay its ongoing administrative expenses and its liabilities for the ensuing twelve months as they normally fall due.

The Company's Common Shares are listed for trading on the TSXV under the symbol "FLT" and the Frankfurt Stock Exchange under the symbol "A2AMGZ", and are quoted on the OTCQX Venture Market in the United States under the symbol "TAKOF".

COVID-19

On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. In mid-March 2020, federal, provincial, and local authorities in Canada, the United States, and other nations began to significantly restrict the ability of people to leave their homes and carry out normal day-day activities. These measures will have a significant, negative effect on the economy of all nations for an uncertain period of time. The duration and impact of COVID-19 is unknown at this time and it is not possible to reliably estimate the impact that the length and severity of these developments will have on the financial results and conditions of the Company in future periods.

2. BASIS OF PREPARATION

Statement of Compliance

These condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, and on a basis consistent with the accounting policies disclosed in the Company's annual audited consolidated financial statements for the year ended December 31, 2020. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by IASB and interpretations issued by IFRIC. These condensed interim consolidated financial statements should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2020.

These condensed interim consolidated financial statements of the Company were approved by the Board of Directors on November 15, 2021.

Basis of Presentation

These unaudited condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial instruments which are measured at fair value. All financial information is presented in Canadian dollars unless otherwise noted and is the presentation currency of the Company.

Basis of Consolidation

These condensed interim consolidated financial statements incorporate the financial statements of the Company and its wholly owned subsidiary, Drone Delivery Canada Inc and Drone Delivery USA Inc. All intercompany transactions, balances, income and expenses are eliminated upon consolidation.

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

3. TRADE AND OTHER RECEIVABLES

	S	eptember 30, 2021	December 31 2020
Trade receivables	\$	7,103 \$	60,850
Other receivables		109,878	461,998
	\$	116,981 \$	522,848

4. PATENTS

C	o	S	t

Balance, December 31, 2019	\$ 695,881
Additions	67,965
Balance, December 31, 2020	\$ 763,846
Additions	61,301
Balance, September 30, 2021	\$ 825,147

Accumulated Depreciation

Balance, September 30, 2021	\$ 24,396
Depreciation	10,635
Balance, December 31, 2020	\$ 13,761
Depreciation	9,642
Balance, December 31, 2019	\$ 4,119

Carrying Value

At December 31, 2020	\$ 750,085
At September 30, 2021	\$ 800,751

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

5. EQUIPMENT

				Assets		
	Lab &		Flight	Under	Drone	
Cost	Other	Office	Equipment	Construction	Parts	Total
Balance, December 31, 2019	\$ 423,987	\$ 472,045	\$ 569,520	\$ 576,997	\$ 206,299	\$ 2,248,848
Additions		19,550	-	264,511	178,480	462,541
Transfers from assets under construction & drone parts		-	547,650	(419,219)	(128,431)	-
Balance, December 31, 2020	\$ 423,987	\$ 491,595	\$ 1,117,170	\$ 422,289	\$ 256,348	\$ 2,711,389
Additions	-	-	-	80,194	374,180	454,374
Disposals	-	-	(120,677)	-	-	(120,677)
Transfers from assets under						
construction	-	-	263,212	(53,637)	(209,575)	-
Balance, September 30, 2021	\$ 423,987	\$ 491,595	\$ 1,259,705	\$ 448,846	\$ 420,953	\$ 3,045,086
Accumulated Depreciation						
Balance, December 31, 2019	\$ 79,843	\$ 100,196	\$ 15,449	\$ -	\$ -	\$ 195,488
Depreciation	76,249	95,541	140,547	-	-	312,337
Balance, December 31, 2020	\$ 156,092	\$ 195,737	\$ 155,996	\$ -	\$ -	\$ 507,825
Depreciation	43,567	53,741	139,529	-	-	236,837
Disposal	-	-	(48,751)	-	-	(48,751)
Balance, September 30, 2021	\$ 199,659	\$ 249,478	\$ 246,774	\$ -	\$ -	\$ 695,911
Carrying Value						
At December 31, 2020	\$ 267,895	\$ 295,858	\$ 961,174	\$ 422,289	\$ 256,348	\$ 2,203,564
At September 30, 2021						

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

6. TRADEMARKS

	 104,489
Additions	10,117
Balance, December 31, 2020	\$ 94,372
Additions	72,897
Balance, December 31, 2019	\$ 21,475

7. LEASEHOLD IMPROVEMENTS

Balance, December 31, 2019	\$ 1,332,807
Additions	54,834
Balance, December 31, 2020	\$ 1,387,641
Additions	6,500
Balance, September 30, 2021	\$ 1,394,141
Accumulated Depreciation	
Balance, December 31, 2019	\$ 70,819
Depreciation	317,644
Balance, December 31, 2020	\$ 388,463
Depreciation	236,647
Balance, September 30, 2021	\$ 625,110
Carrying Value	
At December 31, 2020	\$ 999,178
At September 30, 2021	\$ 769,031

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

8. RIGHT-OF-USE ASSETS

Balance, September 30, 2021	\$ 401,558
Depreciation	(138,127)
Additions	97,411
Balance, December 31, 2020	\$ 442,274
Depreciation	(183,275)
Additions	21,215
Balance, December 31, 2019	\$ 604,334

Right of use assets consists of office, testing and operational facility leases and are amortized over an average useful life of 58.5 months.

Maturity Analysis - Contractual Undiscounted Cash Flows

Balance, September 30, 2021	\$ 504,050
Greater than one year	277,089
Less than one year	\$ 226,961
As at September 30, 2021:	

Not included in the right-of uses assets is a five-year lease extension option for the Company's two facilities in Vaughan and two-year lease extension for another facility Vaughan. The lease extension is available to the Company should it choose to exercise its option at amount that is prevailing in the market at the time of renewal. During the three months ended September 30, 2021, the Company signed a two year lease for a new commercialization centre in Ontario, resulting in an addition to a right-of-use asset of \$54,982. Additions to right-of-use assets for the nine months ended September 30, 2021 include the new facility located in Ontario, and the lease extension executed in the second quarter of 2021.

9. TRADE AND OTHER PAYABLES

	Septe	ember 30, 2021	December 31, 2020
Trade accounts payable and accrued liabilities	\$	1,491,757 \$	1,619,762
Deferred Revenue		443,000	167,888
	\$	1,934,757	1,787,650

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

LEASE OBLIGATIONS

At the commencement date of the leases, the lease liability was measured at the present value of the lease payments that were not paid at that date. The lease payments are discounted using an interest rate of 10%, which is the Company's incremental borrowing rate. The continuity of the lease liabilities are presented in the table below:

Balance, December 31, 2019	\$ 620,095
Additions	21,215
Accretion expense	\$ 55,693
Lease payments	(212,866)
Balance, December 31, 2020	\$ 484,137
Additions	97,411
Accretion expense	33,055
Lease payments	\$ (164,331)
Balance, September 30, 2021	\$ 450,272
As at September 30, 2021:	
Less than one year	\$ 190,836
Greater than one year	259,436
Total lease obligation	\$ 450,272

Occupancy Leases

On January 1, 2020, the Company entered into an office lease agreement with a corporation controlled by a former director to lease office space at \$ 32,000 to \$ 33,000 per year. The lease commenced on January 1, 2020 and expires on January 1, 2022.

On February 4, 2019, the Company entered into a lease for a 16,000 square foot operations facility in Vaughan, Ontario, obliging the Company to make minimum monthly lease payments between \$11,404 and \$12,746 for five years. The lease will expire in the year ended December 31, 2024.

The Company entered into a lease for a drone testing facility in Vaughan, Ontario, obliging the Company to make minimum monthly lease payments of \$2,000 until December 31, 2021. On June 1, 2021, the Company extended this lease for an additional two year until December 31, 2023.

During the three months ended September 30, 2021, the Company entered into a two year lease for a new commercialization centre in Ontario, commencing September 1, 2021, obliging the Company to make minimum monthly lease payments of \$2,500 until August 31, 2023.

Notes to Condensed Interim Consolidated Financial Statements (Expressed in Canadian dollars) (Unaudited)

11. CAPITAL STOCK

(a) AUTHORIZED

Unlimited number of common and special shares, without par value

(b) ISSUED

On March 25, 2019, the Company closed a prospectus offering, pursuant to which it issued an aggregate of 8,350,000 units (the "March 2019 Units"), at a price of \$1.20 per March 2019 Unit (the "March 2019 Issue Price"), for aggregate gross proceeds of \$10,020,000.

Each March 2019 Unit consisted of one common share and one-half of one common share purchase warrant (each whole common share purchase warrant a "March 2019 Warrant"). Each March 2019 Warrant, subject to customary adjustments, shall be exercisable into one common share at an exercise price of \$1.50 per common share for a period of two years from the closing of the offering, subject to certain conditions. Total cash costs of issue amounted to \$968,590.

The 4,175,000 warrants issued in conjunction with the offering carried a \$1.50 exercise price and a term of two years. These warrants were assigned a grant date fair value of \$1,340,175 using the Black-Scholes option pricing model, based on a risk-free rate of 1.48%, an expected life of 2 years, an expected volatility of 67.50% and an expected dividend yield of 0%.

The underwriters were issued an aggregate of 250,500 broker warrants and were paid a cash commission equal to 6% of the gross proceeds raised in respect of the March 25, 2019 prospectus offering. Each broker warrant entitles the holder to one March 2019 Unit at the March 2019 Issue Price until March 25, 2021. The 250,500 broker warrants issued in conjunction with offering carried a \$1.20 exercise price and a term of two years. These broker warrants were assigned a grant date fair value of \$99,474 using the Black-Scholes option pricing model, based on a risk-free rate of 1.48%, an expected life of 2 years, an expected volatility of 67.50% and an expected dividend yield of 0%.

On April 12, 2019, the Underwriters of the March 25, 2019 prospectus offering partially exercised their over-allotment option in respect of the March 25, 2019 prospectus offering, purchasing an additional 344,200 common shares in the Company and 626,250 March 2019 Warrants of the Company, for additional gross proceeds of \$482,353. Commissions of \$28,941 were paid, representing 6% of the gross proceeds raised in respect of this partial exercise of the over-allotment option.

Under the terms of the over-allotment exercise, an aggregate of 23,951 broker warrants were issued, on April 12, 2019 with an exercise price of \$1.20, expiring March 25, 2021. These broker warrants were assigned a grant date fair value of \$9,985 using the Black-Scholes option pricing model, based on a risk-free rate of 1.63%, an expected life of 1.95 years, an expected volatility of 66.94% and an expected dividend yield of 0%.

On August 5, 2020, the Company closed a prospectus offering, pursuant to which it issued an aggregate of 13,225,000 units (the "August 2020 Units") which included the exercise of the full over allotment option, at a price of \$0.70 per August 2020 Unit (the "August 2020 Issue Price"), for aggregate gross proceeds of \$9,257,500.

Each August 2020 Unit consisted of one common share and one-half of one common share purchase warrant (each whole common share purchase warrant a "August 2020 Warrant"). Each August 2020 Warrant, subject to customary adjustments, shall be exercisable into one common share at an exercise price of \$0.95 per common share for a period of two years from the closing of the offering, subject to certain conditions. Total cash costs of issue amounted to \$907,023.

The 6,612,500 warrants issued in conjunction with the offering carried a \$0.95 exercise price and a term of two years. These warrants were assigned a grant date fair value of \$1,529,472 using the Black-Scholes option pricing model, based on a risk-free rate of 0.27%, an expected life of 2 years, an expected volatility of 65.50% and an expected dividend yield of 0%.

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

11. CAPITAL STOCK (continued)

The underwriters were issued an aggregate of 793,500 broker warrants and were paid a cash commission equal to 6% of the gross proceeds raised in respect of the August 5, 2020 prospectus offering. Each broker warrant entitles the holder to one August 2020 Unit at the August 2020 Issue Price until August 5, 2022. The 793,500 broker warrants issued in conjunction with the offering carried a \$0.70 exercise price and a term of two years. These broker warrants were assigned a grant date fair value of \$243,605 using the Black-Scholes option pricing model, based on a risk-free rate of 0.27%, an expected life of 2 years, an expected volatility of 65.50% and an expected dividend yield of 0%.

On December 22, 2020, the Company closed a second prospectus offering in the fiscal year, pursuant to which it issued an aggregate of 15,686,000 units (the "December 2020 Units") which included the exercise of the full over allotment option, at a price of \$0.88 per December 2020 Unit (the "December 2020 Issue Price"), for aggregate gross proceeds of \$13,803,680.

Each December 2020 Unit consisted of one common share and one-half of one common share purchase warrant (each whole common share purchase warrant a "December 2020 Warrant"). Each December 2020 Warrant, subject to customary adjustments, shall be exercisable into one common share at an exercise price of \$1.20 per common share for a period of two years from the closing of the offering, subject to certain conditions. Total cash costs of issue amounted to \$1,147,861.

The 7,843,000 warrants issued in conjunction with the offering carried a \$1.20 exercise price and a term of two years. These warrants were assigned a grant date fair value of \$1,534,874 using the Black-Scholes option pricing model, based on a risk-free rate of 0.22%, an expected life of 2 years, an expected volatility of 63.70% and an expected dividend yield of 0%.

The underwriters were issued an aggregate of 941,160 broker warrants and were paid a cash commission equal to 6% of the gross proceeds raised in respect of the December 22, 2020 prospectus offering. Each broker warrant entitles the holder to one December 2020 Unit at the December 2020 Issue Price until December 22, 2022. The 941,160 broker warrants issued in conjunction with the offering carried a \$0.88 exercise price and a term of two years. These broker warrants were assigned a grant date fair value of \$257,877 using the Black-Scholes option pricing model, based on a risk-free rate of 0.22%, an expected life of 2 years, an expected volatility of 63.70% and an expected dividend yield of 0%.

12. STOCK OPTIONS

The following table reflects the continuity of stock options for the nine months ended September 30, 2021 and 2020:

		Weighted
	Number of Stock	Average
	Options Outstanding	Exercise Price
Balance, December 31, 2019	17,780,000 \$	1.10
Granted	2,915,000	0.70
Expired	(650,000)	1.80
Exercised	(1,910,000)	0.50
Balance, September 30, 2020	18,135,000 \$	1.07
Balance, December 31, 2020	16,975,000	1.12
Exercised	(9,356,662)	1.22
Granted	300,000	1.70
Balance, September 30, 2021	7,918,338 \$	1.04

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

12. STOCK OPTIONS (continued)

During the three month and nine months ended September 30, 2021 the Company granted nil and 300,000 options respectively to purchase common shares of the Company to certain consultants and employees. Each option is exercisable at a price of \$1.70 for a five year term. The fair value of \$335,320 was assigned to these options, estimated using the Black-Scholes valuation model with the following weighted average assumptions: dividend yield 0%; expected volatility of 79.0%; a risk-free rate of return of 0.61% and expected life of 5 years. The options vest at a rate of one third every six months from the date of the grant.

The following table reflects options outstanding as at September 30, 2021:

	Exercise	Weighted Average	Options
Expiry Date	Price	Life Remaining	Outstanding
July 20, 2022	0.50	0.80 years	600,000
January 5, 2023	1.00	1.27 years	420,000
March 2, 2023	1.80	1.42 years	1,575,000
August 30, 2024	1.00	2.92 years	2,075,004
September 24, 2025	0.70	3.99 years	2,208,334
November 9, 2025	0.70	4.11 years	740,000
February 4, 2026	1.70	4.35 years	200,000
March 4, 2026	1.70	4.43 years	100,000
Balance, September 30, 2021	1.04	2.84 years	7,918,338

13. WARRANTS

	Number of Warrants Outstanding	Weighted Average Exercise Price
Balance, December 31, 2019	5,075,701 \$	1.48
Issued	7,406,000	0.92
Balance, September 30, 2020	12,481,701 \$	1.15
Balance, December 31, 2020	21,265,261 \$	1.16
Issued	422,631	1.17
Exercised	(4,775,761)	1.18
Expired	(3,380,213)	1.49
Balance, September 30, 2021	13,531,918 \$	1.07

During the three months and nine months ended September 30, 2021, nil and 4,775,761 warrants respectively were exercised into common shares of the company for proceeds of \$nil and \$5,618,643. The warrants exercised included 845,262 broker warrants, which yielded an issuance of 422,631 warrants. On March 25, 2021, 3,380,213 warrants expired unexercised.

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

13. WARRANTS (continued)

The following table reflects the warrants outstanding as at September 30, 2021:

Weighted

		Exercise	Average	Warrants	Black - Scholes
Expiry Date	Туре	Price	Life Remaining	Outstanding	Value
August 5, 2022	Broker Warrant	0.70	0.85	436,425	170,523
August 5, 2022	Warrant	0.95	0.85	5,506,051	1,269,654
December 22, 2022	Broker Warrant	0.88	1.23	658,812	206,302
December 22, 2022	Warrant	1.20	1.23	6,930,630	1,365,965
	\$	1.07	1.06	13,531,918	\$ 3,012,444

On August 5, 2020, the underwriters were issued an aggregate of 793,500 broker warrants in respect of the August 5, 2020 prospectus offering. Each broker warrant entitles the holder to one August 2020 Unit at the August 2020 Issue Price until August 5, 2022. The 793,500 broker warrants issued in conjunction with the offering carried a \$0.70 exercise price and a term of two years. These broker warrants were assigned a grant date fair value of \$243,605 using the Black-Scholes option pricing model, based on a risk-free rate of 0.27%, an expected life of 2 years, an expected volatility of 65.50% and an expected dividend yield of 0%.

On December 22, 2020, the underwriters were issued an aggregate of 941,160 broker warrants in respect of the December 22, 2020 prospectus offering. Each broker warrant entitles the holder to one December 2020 Unit at the December 2020 Issue Price until December 22, 2022. The 941,160 broker warrants issued in conjunction with the offering carried a \$0.88 exercise price and a term of two years. These broker warrants were assigned a grant date fair value of \$257,878 using the Black-Scholes option pricing model, based on a risk-free rate of 0.22%, an expected life of 2 years, an expected volatility of 63.70% and an expected dividend yield of 0%.

14. BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

Basic loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted loss per share, which reflects the maximum possible dilution from the potential exercise of warrants and stock options, is the same as basic loss per share for the nine months ended September 30, 2021 and 2020.

15. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial Instruments

The Company's financial instruments include cash and cash equivalents, trade receivables, trade and other payables, and lease obligations.

The carrying amounts shown in the statement of financial position are as follows:

Notes to Condensed Interim Consolidated Financial Statements

(Expressed in Canadian dollars) (Unaudited)

15. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

	Category		September 30, 2021	December 31, 2020
Cash and cash equivalents	FVTPL	\$	31,071,646	\$ 23,464,255
Trade receivables	Amortized Cost	\$	7,103	\$ 60,850
Trade and other payables	Amortized Cost	\$	1,934,757	\$ 1,787,650
Lease obligation	Amortized Cost	\$	450,272	\$ 484,137

Financial Instruments

IFRS 7 establishes a fair value hierarchy for financial instruments measured at fair value that reflects the significance of inputs in making fair value measurements as follows:

Level 1 - applied to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly such as quoted prices for similar assets or liabilities in active markets or indirectly such as quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions.

Level 3 - applies to assets or liabilities for which there are unobservable market data.

The carrying value of trade receivables, trade and other payables approximate their fair value due to the short-term nature of these instruments. Pursuant to IFRS 7, the fair value of cash and cash equivalents is measured on a recurring basis based on Level 1 inputs.

Risk Management Disclosures

The Company is exposed to risks of varying degrees of significance, which could affect its ability to achieve its strategic objectives for growth. The main objectives of the Company's risk management process are to ensure that risks are properly identified and that the capital base is adequate in relation to these risks. The principal financial risks to which the Company is exposed is described below.

Financial Risks

Risk management is carried out by the Company's management team under policies approved by the Board of Directors. The Board of Directors also provides regular guidance for overall risk management.

Credit Risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash and cash equivalents, and trade and other receivables. Trade and other receivables consists primarily of harmonized taxes receivable from the Government of Canada. Cash and cash equivalents are held with reputable Canadian chartered banks and money market mutual funds, the balances of which are closely monitored by management. Management believes that the credit risk with respect to financial instruments included in cash and cash equivalents, is minimal.

Notes to Condensed Interim Consolidated Financial Statements (Expressed in Canadian dollars) (Unaudited)

16. RELATED PARTY TRANSACTIONS AND BALANCES

a) Key Management Compensation:

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company's Board of Directors, executive officers and certain consultants.

During the nine months ended September 30, 2021, and 2020 the following compensation amounts were incurred in respect of key management personnel:

	Septe	September 30, 2021	
Consulting fees and salaries	\$	2,009,213 \$	1,519,609
Share based compensation		780,237	1,665,468
	\$	2,789,450 \$	3,185,077

During the nine months ended September 30, 2021 and 2020, the Company allocated the \$2,009,213 (2020 - \$1,519,609) of consulting fees and salaries based on the nature of services provided: expensed \$1,122,000 (2020 - \$1,112,000) to consulting; and expensed \$887,213 (2020 - \$397,609) to personnel expenses.

As at September 30, 2021, consulting fees of \$nil (December 31, 2020 - \$440,000) remain unpaid are included in trade and other payables. Consulting fees of \$23,500 (December 31, 2020 - \$23,500) paid in advance are included in prepaid expenses.

The Company has an employment agreement with its CEO which provides that in the event the CEO's employment is terminated by the Company without cause, (i) a lump sum payment equal to 12 months' salary, or (ii) within twenty four months of, or in anticipation within 180 days of, a change in control, a termination payment equal to 18 months' salary, at \$429,000 per annum, is payable. If the termination had occurred on September 30, 2021, the amount payable under this agreement would be \$429,000.

The Company has an employment agreement with its CFO which provides that the CFO is entitled to, in the event that the CFO's employment is terminated (i) by the Company without cause, the greater of one month per year of service and six months' of notice or a termination payment in lieu thereof (as at September 30, 2021 representing a minimum payment of \$108,000), or (ii) by the Company within twelve months following or within 180 before in anticipation of a change in control, a lump-sum payment equal to twelve months' salary (as at September 30, 2021 representing a payment of \$216,000).

The Company has consulting agreements with a corporation controlled by a former director, a corporation controlled by a former Vice President, a corporation controlled by the former Chief Executive Officer and a corporation controlled by the former Chief Technology Officer, which provide that in the event the consulting agreements are terminated without cause, a termination payment for consulting fees for the remainder of the term, ranging from \$210,000 to \$282,000 per annum depending on the agreement, is payable. If all such terminations had occurred on September 30, 2021, the total amount payable under the agreements would be \$1,354,000

- b) During the nine months ended September 30, 2021, rent of \$24,867 (2020 \$33,939) was paid to a company jointly controlled by the former Chief Technology Officer and the former Chief Executive Officer of the Company. As at September 30, 2021, \$nil was included in accounts payable and accrued liabilities (December 31, 2020 \$nil).
- c) During the nine months ended September 30, 2021, legal fees of \$201,371 (2020 \$196,716) were accrued or paid to a law firm in which a director of the Company is a partner. As at September 30, 2021, \$43,113 was included in accounts payable and accrued liabilities (December 31, 2020 \$162,183).